Sanofi | SNY - Net Income




Sanofi reported EUR2.82B in Net Income for its fiscal quarter ending in September of 2024.

Net Income Change Date
AbbVie USD -22000000 1.58B Dec/2024
Amgen USD 627M 2.2B Dec/2024
AstraZeneca USD 1.5B 71M Dec/2024
Bristol-Myers Squibb USD 72M 1.14B Dec/2024
Canopy Growth CAD -128293000 1.15M Sep/2024
Corcept Therapeutics USD 47.21M 11.72M Sep/2024
Drreddys Laboratories INR 12.55B 1.37B Sep/2024
Eli Lilly USD 4.41B 3.44B Dec/2024
Galapagos EUR 25.31M 75.74M Dec/2024
Genmab DKK 3.84B 2.58B Dec/2024
GlaxoSmithKline GBP 414M 472M Dec/2024
Glaxosmithkline GBP -58000000 1.23B Sep/2024
Indivior 4M 111M Sep/2024
J&J USD 3.43B 737M Dec/2024
Merck USD 3.74B 586M Dec/2024
Novartis USD 2.82B 371M Dec/2024
Novartis USD 3.19B 57M Sep/2024
Pacira USD -143466000 162.36M Sep/2024
Perrigo USD -21000000 87.4M Sep/2024
Pfizer USD 410M 4.06B Dec/2024
Prestige Brands USD 61.03M 6.65M Dec/2024
Roche Holding CHF 1.01B 2.12B Dec/2024
Sanofi EUR 2.82B 1.7B Sep/2024
Sanofi EUR 2.82B 1.7B Sep/2024
Supernus Pharmaceuticals USD 38.5M 18.58M Sep/2024
UCB EUR 104M 72M Jun/2024
Zoetis USD 581M 101M Dec/2024